Dry eye disease is a complex condition involving tear film instability, hyperosmolar stress, ocular surface damage, and inflammation. As scientific understanding continues to evolve, research is increasingly looking beyond conventional lubrication toward ingredients that can help protect the ocular surface at a cellular and molecular level.

The TFOS DEWS III Management and Therapy report, published in 2025, includes a dedicated discussion of ectoine-containing products and summarizes findings from both human and preclinical studies.

Together, the evidence highlights ectoine as a promising osmoprotective ingredient for the development of ophthalmic and dry eye applications.

Dry eye is more than a lack of tears

The tear film forms a protective interface between the eye and the external environment. When this film becomes unstable, evaporation can increase and the tear fluid may become hyperosmolar.

This hyperosmolar environment places stress on epithelial cells and can contribute to:

• ocular surface irritation

• corneal damage

• inflammatory signalling

• reduced goblet cell function

• impaired mucin production

• further tear film instability

This can create a self-perpetuating cycle in which stress, inflammation, and tear film dysfunction reinforce one another.

For modern dry eye product development, the goal is therefore not only to lubricate the surface, but also to support the biological structures responsible for ocular surface stability.

What is medEctoin®?

medEctoin® is pharmaceutical-grade Ectoin®, a naturally occurring extremolyte produced by microorganisms to protect themselves under challenging environmental conditions.

On the ocular surface, ectoine acts as a natural osmoprotectant. Through its water-binding and structure-stabilizing properties, it helps protect proteins, biological membranes, and cells exposed to hyperosmolar stress.

This creates a broader protective approach that extends beyond temporary lubrication.

Key functional properties include:

Osmoprotection
Ectoine supports cells exposed to the elevated osmotic stress associated with dry eye disease.

Protein and membrane stabilization
It helps preserve the structural integrity of proteins and biological membranes under stressful conditions.

Ocular surface protection
By stabilizing cellular structures, ectoine may help strengthen the resilience of the challenged ocular surface.

Human evidence: improved symptoms and tear film stability

A prospective study included 18 participants with dry eye disease who used a preservative-free, ectoine-containing eye spray three times daily for approximately two weeks.

Following treatment, the study reported:

• reduced dry eye symptoms

• increased noninvasive tear breakup time, also known as NIBUT

NIBUT measures how long the tear film remains stable before it begins to break up. A longer breakup time indicates greater tear film stability.

Although the study was small and did not include a control group, its findings provide encouraging human evidence that an ectoine-containing product may support both subjective symptom relief and objective tear film stability.

Preclinical evidence: concentration-dependent corneal protection

Further evidence comes from a desiccation-induced murine model of dry eye.

In this vehicle-controlled study, topical ectoine protected the cornea in a concentration-dependent manner. At concentrations of 1.0% and 2.0%, ectoine was associated with:

• improved corneal regularity

• reduced corneal staining

• reduced signs of corneal damage

• suppression of elevated proinflammatory cytokines and chemokines toward near-normal levels

These findings suggest that ectoine may provide more than physical surface protection. The observed changes in inflammatory mediators indicate a potential role in modulating the biological response to ocular surface stress.

Because these results were obtained in an animal model, they should not be interpreted as direct clinical proof. However, they provide valuable mechanistic support for further research and product development.

Supporting goblet cells and mucin production

Goblet cells play a central role in maintaining a healthy ocular surface. They produce mucins that help tears spread evenly across the eye and allow the tear film to adhere to the epithelial surface.

In dry eye disease, goblet cell density and mucin production may decline, further weakening tear film stability.

In another murine dry eye model, topical 2% ectoine:

• significantly reduced corneal damage

• increased goblet cell density

• supported mucin production compared with the vehicle control

These effects were associated with restoration of the disrupted IL-13 and IFN-γ signalling balance, an inflammatory pathway involved in goblet cell function and ocular surface homeostasis.

The findings indicate that ectoine may support several interconnected elements of ocular surface health, including corneal integrity, goblet cell function, mucin production, and inflammatory balance.

From osmoprotection to inflammatory balance

The available evidence suggests that ectoine addresses several processes involved in dry eye disease:

1. Protection from hyperosmolar stress

Ectoine helps stabilize cells and biological structures exposed to an imbalanced tear environment.

2. Support for tear film stability

Human findings indicate improvements in noninvasive tear breakup time following the use of an ectoine-containing eye spray.

3. Corneal protection

Preclinical studies demonstrate reduced corneal staining and damage, with stronger effects observed at higher ectoine concentrations.

4. Modulation of inflammatory responses

Animal models show reductions in elevated cytokines and chemokines, alongside improvements in inflammatory signalling balance.

5. Support for goblet cells and mucin

By supporting goblet cell density and mucin production, ectoine may help reinforce the foundations of a stable and functional tear film.

What the evidence means for ophthalmic product development

The studies summarized in TFOS DEWS III reflect growing scientific interest in ectoine for dry eye management.

The evidence currently includes both human and preclinical findings. While additional large, controlled clinical studies would strengthen the clinical evidence base, the available data provide a scientifically relevant foundation for the use of ectoine in ophthalmic formulations.

For developers, medEctoin® offers a pharmaceutical-grade source of Ectoin® suitable for concepts focused on:

• dry eye management

• ocular surface protection

• osmoprotection

• tear film stabilization

• preservative-free formulations

• support for stressed and sensitive eyes

Developing evidence-based eye care with medEctoin®

Dry eye is a multifactorial condition requiring more than a single mode of action. Ingredients that support cellular protection, tear film stability, and ocular surface homeostasis can therefore play an important role in future formulation strategies.

medEctoin® combines the natural protective properties of Ectoin® with pharmaceutical-grade quality for the development of innovative ophthalmic and dry eye applications.

Are you exploring medEctoin® for your next development project?

Let us create evidence-based solutions for better eye care.